1. Scrip

More power to CMO as Astellas aims for integrated development

 
• By Ian Haydock

As part of efforts to improve the global integration and direction of its development strategy, Astellas is expanding the responsibilities of its chief medical officer (CMO), a position created within the firm only last year.

As part of efforts to improve the global integration and direction of its development strategy, Astellas is expanding the responsibilities of its chief medical officer (CMO), a position created within the firm only last year.

From the start of its next fiscal year on 1 April, the Japanese company's heads of global development, global regulatory affairs, global clinical and research quality assurance, and global quality assurance

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.